Janssen 54767414 MMY3021 “Auriga”
A Randomized Study of Daratumumab plus Lenalidomide vs. Lenalidomide Alone vs Maintenance Treatment in Patients with Newly Diagnosed Mulitple Myeloma Who Are Minimal Residual Disease Positive after Frontline Autologous Stem Cell Transplant.
Janssen 54767414 MMY2065 “Lynx”
A Phase 2 Study Comparing Daratumumab Subcutaneous Administration in Combination with Carfilzomib, and Dexamethasone (DKd) vs Carfilzomib and Dexamethasone (Kd) in Subjects with Multiple Myeloma who have been Previously treated with Daratumumab IV.
GSK 213304 EAP (Expanded Access Program)
Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti- CD38 Antibody
©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.